Cancer
Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel
Published in Medical Letter on the CDC and FDA, March 23rd, 2008
Genta Incorporated (NASDAQ:GNTA) announced the Company has entered into an exclusive worldwide licensing agreement with Daiichi Sankyo Company, Limited (TYO: 4568) for the development and commercialization of tesetaxel (formerly known as DJ-927). As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with other taxanes, such as paclitaxel (Taxol(R)) and docetaxel (Taxotere(R); sanofi aventis). Moreover, unlike other oral taxanes that are currently in clinical development, nerve damage has not been a prominent side effect of tesetaxel....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Bronchiectasis
Pharmaxis' First Steps into China - Monoclonal Antibodies
New monoclonal antibodies research reported from University of Connecticut - Pulmonary Hypertension
National Institute for Health and Clinical Excellence (NICE) Releases Appraisal Consultation Document on Treatment of Pulmonary Arterial Hypertension in Adults - Regulatory Actions
Research data from University of Maryland update understanding of regulatory actions - Salmonellosis
Findings from R. Kumar and co-authors broaden understanding of salmonellosis - Weapons of Mass Destruction
Treating Victims of Weapons of Mass Destruction - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
